Maximus, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 8, 2024 and accepted by EDGAR at Aug 8, 2024, 17:07 ET.
Management's discussion and analysis
As filed, 38,846 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion is intended to help the reader understand our business, financial condition, results of operations, liquidity and capital resources. You should read this discussion in conjunction with "Risk Factors," "Special Note Regarding Forward-Looking Statements," and our financial statements and related notes included in our Annual Report on Form 10-K for fiscal year 2023 filed with the Securities and Exchange Commission on November 16, 2023 (the "2023 Form 10-K") and elsewhere in this Quarterly Report on Form 10-Q, as applicable.
Business Overview
Maximus, under its mission of Moving People Forward, helps millions of people access the vital government services they need. With almost 50 years of experience working with local, state, federal, and international government clients, we proudly design, develop, and deliver innovative and impactful programs that change lives. We are driven to strengthen communities and improve the lives of those we serve.
We create value for our customers through our ability to translate health and human services public policy into operating models that achieve outcomes for governments at scale. Our work covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. These services benefit from a market with increasing demographic demand, constrained government budgets, and an increased focus on technology. We also demonstrate the ability to move quickly, ranging from digitally enabled contact center support services for natural disaster response to swift establishments of public health and safety initiatives, examples of which occurred during the COVID-19 pandemic. Our organic growth through increased contract scope and entry into new markets has been supplemented by strategic acquisitions. Most notably, our acquisitions of VES Group, Inc. ("VES"), a leading provider of medical disability examinations ("MDE") to the United States ("U.S.") Department of Veterans Affairs ("VA"); the Federal business of Attain, LLC ("Attain"), a provider of technology consulting and systems integration services; and a service contract with the U.S. Department of Education, under our Aidvantage brand, have supplemented our organic growth and allowed expansion into new markets.
In fiscal year 2022, we introduced our refreshed three-to-five-year strategic plan, which we believe will further expand our business. Having moved past the major impacts of the COVID-19 pandemic, we believe we are in a strong position to capitalize on organic growth opportunities in our core business, as reflected in the following three pillars of our refreshed strategy.
- Customer Services, Digitally Enabled. Elevate the customer experience to achieve higher levels of satisfaction, performance, and outcomes through intelligent automation and cognitive computing.
- Future of Health. Help governments meet the rising demand for health services by growing our clinical capabilities to improve the health of people and their communities.
- Advanced Technologies for Modernization. Further our credibility as a technology leader, enabling the transformation of government programs to be resilient, dynamic, integrated, and equitable.
Financial Overview
A number of factors have affected our results for the three and nine months ended June 30, 2024. More detail on these changes is presented below within our "Results of Operations" section.
Results of Operations
The following table sets forth items from our consolidated statements of operations for the three and nine months ended June 30, 2024, and June 30, 2023.
(dollars in thousands, except per share data)
| Table MD&A 1: Consolidated Results of Operations | For the Three Months Ended June 30, 2024 | June 30, 2023 | For the Nine Months Ended June 30, 2024 | June 30, 2023 |
|---|---|---|---|---|
| Revenue | $1,314,929 | $1,188,677 | $3,990,327 | $3,644,775 |
| Cost of revenue | 982,615 | 924,313 | 3,040,370 | 2,907,061 |
| Gross profit | 332,314 | 264,364 | 949,957 | 737,714 |
| Gross profit percentage | 25.3% | 22.2% | 23.8% | 20.2% |
| Selling, general, and administrative expenses | 167,033 | 182,545 | 504,682 | 471,445 |
| Selling, general, and administrative expenses as a percentage of revenue | 12.7% | 15.4% | 12.6% | 12.9% |
| Amortization of intangible assets | 23,542 | 23,431 | 68,532 | 70,599 |
| Operating income | 141,739 | 58,388 | 376,743 | 195,670 |
| Operating margin | 10.8% | 4.9% | 9.4% | 5.4% |
| Interest expense | 20,555 | 21,026 | 62,428 | 63,631 |
| Other expense/(income), net | 809 | 1,005 | 475 | (79) |
| Income before income taxes | 120,375 | 36,357 | 313,840 | 132,118 |
| Provision for income taxes | 30,623 | 5,494 | 79,430 | 29,472 |
| Effective tax rate | 25.4% | 15.1% | 25.3% | 22.3% |
| Net income | $89,752 | $30,863 | $234,410 | $102,646 |
| Earnings per share: | ||||
| Basic | $1.47 | $0.50 | $3.83 | $1.68 |
| Diluted | $1.46 | $0.50 | $3.81 | $1.67 |
Our business segments have different factors driving revenue fluctuations and profitability. The sections that follow cover these segments in greater detail. Our revenue reflects fees earned for services provided. Cost of revenue consists of direct costs related to labor and related overhead, subcontractor labor, outside vendors, rent, and other direct costs. The largest component of cost of revenue, approximately two-thirds, is labor, including subcontracted labor.
Table MD&A 2: Changes in Revenue, Cost of Revenue, and Gross Profit for the Three Months Ended June 30, 2024
(dollars in thousands)
| Revenue Dollars | % Change | Cost of Revenue Dollars | % Change | Gross Profit Dollars | % Change | |
|---|---|---|---|---|---|---|
| Three months ended June 30, 2023 | $1,188,677 | $924,313 | $264,364 | |||
| Organic effect | 133,211 | 11.2% | 66,178 | 7.2% | 67,033 | 25.4% |
| Disposal of businesses | (7,123) | (0.6)% | (7,905) | (0.9)% | 782 | 0.3% |
| Currency effect compared to the prior period | 164 | —% | 29 | —% | 135 | 0.1% |
| Three months ended June 30, 2024 | $1,314,929 | 10.6% | $982,615 | 6.3% | $332,314 | 25.7% |
23
Table MD&A 3: Changes in Revenue, Cost of Revenue, and Gross Profit for the Nine Months Ended June 30, 2024
(dollars in thousands)
| Revenue Dollars | % Change | Cost of Revenue Dollars | % Change | Gross Profit Dollars | % Change | |
|---|---|---|---|---|---|---|
| Nine months ended June 30, 2023 | $3,644,775 | $2,907,061 | $737,714 | |||
| Organic effect | 372,624 | 10.2% | 164,374 | 5.7% | 208,250 | 28.2% |
| Disposal of businesses | (35,126) | (1.0)% | (37,955) | (1.3)% | 2,829 | 0.4% |
| Currency effect compared to the prior period | 8,054 | 0.2% | 6,890 | 0.2% | 1,164 | 0.2% |
| Nine months ended June 30, 2024 | $3,990,327 | 9.5% | $3,040,370 | 4.6% | $949,957 | 28.8% |
Selling, general, and administrative ("SG&A") expenses
SG&A expense consists of indirect costs related to general management, marketing, and administration. It is primarily composed of labor costs. These costs may be incurred at a segment level, for dedicated resources that are not client-facing, or at a corporate level. Corporate costs are allocated to segments on a consistent and rational basis. Fluctuations in our SG&A expense are primarily driven by changes in our administrative cost base, which is not directly driven by changes in our revenue. As part of our work for the U.S. federal government and many states, we allocate these costs using a methodology driven by the U.S. Federal Cost Accounting Standards.
Our SG&A expense for the three months ended June 30, 2023, included $22.1 million of expenses for investigation and remediation activities related to a cybersecurity event. Notwithstanding this, our SG&A expenses for the nine months ended June 30, 2024, have increased compared to the comparative period. This growth is principally from growth in our administrative base as the business expands.
Amortization of intangible assets
Amortization of intangible assets remained consistent for the three months ended June 30, 2024, as compared to three months ended June 30, 2023. For the nine months ended June 30, 2024, amortization of intangible assets decreased by $2.1 million as compared to nine months ended June 30, 2023. The decline was principally driven by the amortization in full of intangible assets from our Aidvantage acquisition.
Our balance sheet includes intangible assets of $487 million and $37 million from the 2021 VES and 2019 GDIT acquisitions, respectively. These assets, comprising customer relationships, technology, and a medical provider network, continue to support contracts acquired with these acquisitions. The greater part of these assets are being amortized over the remaining nine and five years, respectively. In the event that our expectations change with respect to these acquired contracts, the value of these assets and the estimated remaining lives of these assets may need to be adjusted.
Interest Expense
Our interest expense has remained consistent year-over-year as declines in our debt balance are offset by increased interest rates. Following the amendment of our debt agreement, we continue to mitigate our risk by fixing interest rates on approximately half of our debt. Our near-term capital allocation plan continues to prioritize reducing our debt using our free cash flow.
Provision for Income Taxes
Our effective income tax rate for the three and nine months ended June 30, 2024, was 25.4% and 25.3%, respectively, compared to 15.1% and 22.3% for the three and nine months ended June 30, 2023. Our tax rates in fiscal year 2023 received the benefit of discrete tax benefits from tax credits, which did not recur in fiscal year 2024. For fiscal year 2024, we expect the effective tax rate to be between 24.5% and 25.5%.
U.S. Federal Services Segment
Our U.S. Federal Services Segment delivers end-to-end solutions that help various U.S. federal government agencies better deliver on their mission, including program operations and management, clinical services, and technology solutions. This segment also includes system and application development, Information Technology ("IT") modernization, and maintenance services. Clinical services comprises appeals and assessments services, which includes managing the evaluation process for U.S. veterans and service members on behalf of the U.S. Department of Veterans Affairs ("VA") and certain state-based assessments and appeals work that is part of the segment's heritage. Under Technology Consulting Services ("TCS"), the segment executes on its digital strategy to deliver technology solutions that advance agency missions, including the challenge to modernize, provide better customer experience, and drive process efficiencies.
Table MD&A 4: U.S. Federal Services Segment - Financial Results
(dollars in thousands)
| For the Three Months Ended June 30, 2024 | June 30, 2023 | For the Nine Months Ended June 30, 2024 | June 30, 2023 | |
|---|---|---|---|---|
| Revenue | $683,347 | $583,960 | $2,062,127 | $1,786,202 |
| Cost of revenue | 497,272 | 427,015 | 1,556,053 | 1,383,689 |
| Gross profit | 186,075 | 156,945 | 506,074 | 402,513 |
| Selling, general, and administrative expenses | 79,949 | 82,892 | 247,671 | 229,591 |
| Operating income | 106,126 | 74,053 | 258,403 | 172,922 |
| Gross profit percentage | 27.2% | 26.9% | 24.5% | 22.5% |
| Operating margin percentage | 15.5% | 12.7% | 12.5% | 9.7% |
Our revenue and cost of revenue for the three months ended June 30, 2024, increased 17.0% and 16.5%, respectively, compared to the three months ended June 30, 2023. For the nine months ended June 30, 2024, revenue and cost of revenue growth were 15.4% and 12.5%, respectively, compared to the nine months ended June 30, 2023. All growth in fiscal year 2024 was organic.
Our revenue and margin growth has principally been driven by volume growth and strong performance on our contracts relating to clinical assessments. Our profit margins have grown as the volume growth has allowed for economies of scale.
We anticipate that our U.S. Federal Services Segment will continue to grow for the remainder of fiscal year 2024, driven primarily by additional volumes in clinical services. We anticipate that our full-year operating margin will be around 12.5%.
We continue to monitor the status of announced recompetes of two of our significant contracts:
- The Centers for Medicare & Medicaid Services is currently recompeting the Contact Center Operations contract awarded to us in 2022, which is earlier-than-expected, and for the express purpose of including a labor harmony agreement requirement. In June 2024 we filed a pre-award protest which will be adjudicated by the Government Accountability Office. The Company expects to receive a response prior to the end of fiscal year 2024. The $6.6 billion contract value over a base plus a nine-year period of performance, is equivalent to approximately 10% to 15% of total Company revenue on an annual basis. The contract type is cost-plus-award-fee which traditionally carries low single digit margins. Given the contract's absorption of indirect costs, the impact to consolidated operating income from the absence of this contract would likely be more significant than just the low single digit margin, depending in part on the extent to which we would be able to mitigate the effects. Maximus has consistently met or exceeded all contractual service levels with uninterrupted operations and driven the highest independently measured customer satisfaction in the history of the program. We anticipate continuing to work on this contract uninterrupted until the recompete process, including any subsequent protest actions, is completed. We also believe that, as the incumbent, we have significant operational advantages.
- A majority of the MDE contracts under the VA, which comprise our acquired VES business, had ceilings on claims volumes at the time of award in 2018. Volumes have significantly increased since the passage of the PACT Act, thereby requiring a rebid process. In fiscal year 2023, these contracts together represented between 10% and 15% of our revenue. We anticipate continuing to work on these contracts uninterrupted until the recompete process is completed and that, as the incumbent, we have significant operational advantages.
U.S. Services Segment
Our U.S. Services Segment provides a variety of business process services ("BPS"), such as program administration, assessments, and related consulting work for U.S. state and local government programs. These services support a variety of programs, including the Affordable Care Act ("ACA"), Medicaid, the Children's Health Insurance Program ("CHIP"), Temporary Assistance to Needy Families ("TANF"), and child support programs. Previously, this segment suffered from reduced operating leverage resulting from the pause in Medicaid redeterminations during the COVID-19 pandemic. Redeterminations resumed in late fiscal year 2023, meaning fiscal year 2024 and beyond are demonstrating and should continue to demonstrate recovery of operating leverage and related margin improvement.
Table MD&A 5: U.S. Services Segment - Financial Results
(dollars in thousands)
| For the Three Months Ended June 30, 2024 | June 30, 2023 | For the Nine Months Ended June 30, 2024 | June 30, 2023 | |
|---|---|---|---|---|
| Revenue | $472,298 | $449,061 | $1,448,258 | $1,338,242 |
| Cost of revenue | 351,286 | 350,523 | 1,078,761 | 1,070,090 |
| Gross profit | 121,012 | 98,538 | 369,497 | 268,152 |
| Selling, general, and administrative expenses | 59,531 | 51,536 | 174,032 | 140,793 |
| Operating income | 61,481 | 47,002 | 195,465 | 127,359 |
| Gross profit percentage | 25.6% | 21.9% | 25.5% | 20.0% |
| Operating margin percentage | 13.0% | 10.5% | 13.5% | 9.5% |
Our revenue and cost of revenue for the three months ended June 30, 2024, increased 5.2% and 0.2%, respectively, compared to the three months ended June 30, 2023. For the nine months ended June 30, 2024, our revenue and cost of revenue increased 8.2% and 0.8%, respectively, compared to the nine months ended June 30, 2023. All growth was organic.
Growth in fiscal year 2024 was principally from Medicaid-related activities, a portion of which includes redetermination activities related to the unwinding exercise, resulting in additional volumes in transactions generating revenue on a cost-base which had been built up in anticipation of this growth. This resulted in improvements to our profit margins, that we anticipate returning to normal levels over the coming quarters. We anticipate a full-year operating profit margin of approximately 13%.
Outside the U.S. Segment
Our Outside the U.S. Segment provides BPS for international governments, transforming the lives of people around the world. Helping people find employment, access vital support, and remain healthy, these services include health and disability assessments, program administration for employment services, wellbeing solutions, and other job seeker-related services. We support programs and deliver services in the United Kingdom, including the Health Assessment Advisory Service and the recently awarded replacement contract scheduled to start in the fourth quarter of fiscal year 2024, Functional Assessment Services, and Restart; and Australia, including Workforce Australia, and other employment support and job seeker services in a number of other countries.
Table MD&A 6: Outside the U.S. Segment - Financial Results
(dollars in thousands)
| For the Three Months Ended June 30, 2024 | June 30, 2023 | For the Nine Months Ended June 30, 2024 | June 30, 2023 | |
|---|---|---|---|---|
| Revenue | $159,284 | $155,656 | $479,942 | $520,331 |
| Cost of revenue | 134,057 | 146,775 | 405,556 | 453,282 |
| Gross profit | 25,227 | 8,881 | 74,386 | 67,049 |
| Selling, general, and administrative expenses | 26,647 | 24,122 | 75,249 | 75,936 |
| Operating loss | (1,420) | (15,241) | (863) | (8,887) |
| Gross profit percentage | 15.8% | 5.7% | 15.5% | 12.9% |
| Operating margin percentage | (0.9)% | (9.8)% | (0.2)% | (1.7)% |
26
Table MD&A 7: Outside the U.S. Segment - Changes in Revenue, Cost of Revenue, and Gross Profit for the Three Months Ended June 30, 2024
(dollars in thousands)
| Revenue Amount | % Change | Cost of Revenue Amount | % Change | Gross Profit Amount | % Change | |
|---|---|---|---|---|---|---|
| Three months ended June 30, 2023 | $155,656 | $146,775 | $8,881 | |||
| Organic effect | 10,587 | 6.8% | (4,842) | (3.3)% | 15,429 | 173.7% |
| Disposal of businesses | (7,123) | (4.6)% | (7,905) | (5.4)% | 782 | 8.8% |
| Currency effect compared to the prior period | 164 | 0.1% | 29 | —% | 135 | 1.5% |
| Three months ended June 30, 2024 | $159,284 | 2.3% | $134,057 | (8.7)% | $25,227 | 184.1% |
Table MD&A 8: Outside the U.S. Segment - Changes in Revenue, Cost of Revenue, and Gross Profit for the Nine Months Ended June 30, 2024
(dollars in thousands)
| Revenue Amount | % Change | Cost of Revenue Amount | % Change | Gross Profit Amount | % Change | |
|---|---|---|---|---|---|---|
| Nine months ended June 30, 2023 | $520,331 | $453,282 | $67,049 | |||
| Organic effect | (13,317) | (2.6)% | (16,661) | (3.7)% | 3,344 | 5.0% |
| Disposal of businesses | (35,126) | (6.8)% | (37,955) | (8.4)% | 2,829 | 4.2% |
| Currency effect compared to the prior period | 8,054 | 1.5% | 6,890 | 1.5% | 1,164 | 1.7% |
| Nine months ended June 30, 2024 | $479,942 | (7.8)% | $405,556 | (10.5)% | $74,386 | 10.9% |
This segment has recorded a small loss in fiscal year 2024 as management undertakes steps to improve performance and deliver consistent profitability in this part of our organization. These steps included the divestiture in fiscal year 2024 of our employment services business in Canada and all of our operations in Italy and Singapore. In fiscal year 2023, we disposed of our commercial practice in the United Kingdom and our Swedish operations.
Revenue growth in the quarter was driven by our United Kingdom business, as well as the continued ramp up of contracts in Saudi Arabia.
Revenue from our employment services contracts include payments based upon our ability to place individuals in long-term, sustained employment. We recognize this revenue over the period of performance using estimates of these outcomes, which are typically based upon past performance. Changes in these estimates may have a significant effect on our revenue.
The improvement in the valuation of the British Pound provided an additional benefit to revenue and profit in the first nine months of fiscal year 2024.
We anticipate our Outside the United States Segment will yield slightly above break-even operating margin for the full year.
Liquidity and Capital Resources
Our primary sources of liquidity are cash on hand, cash from operations, and availability under our revolving credit facilities. As of June 30, 2024, we had $102.8 million in cash and cash equivalents. We believe that our current cash position, access to our revolving debt, and cash flow generated from operations should be sufficient for our operating requirements for the next 12 months and beyond, including enabling us to fund required long-term debt repayments, dividends and any share purchases we might choose to make. See "Note 6. Debt and Derivatives" to the Consolidated Financial Statements for a more detailed discussion of our debt financing arrangements.
We have included the following table showing our debt balances as of June 30, 2024, and their effective interest rates.
Table MD&A 9: Balances and interest rates as of June 30, 2024
(dollars in thousands)
| Carrying value | Effective cash interest rate | Interest rate basis | |
|---|---|---|---|
| Term Loan A - Hedged though May 2026 | $500,000 | 3.91% | Fixed rate of 2.31% plus margin. (1) |
| Term Loan A - Hedged through September 2024 | 150,000 | 5.98% | Fixed rate of 4.38% plus margin. (1) |
| Term Loan B | 500,000 | 7.44% | Term SOFR (variable reset) plus 2% margin. |
| Debt held by international subsidiaries | 5,003 | 6.21% | Floating rate, reset quarterly. |
| Debt Principal | $1,155,003 |
(1) Applicable margin ranges between 1% and 2%, based on our leverage ratio.
Our effective cash interest rate reflects the drivers of our cash interest payments as of June 30, 2024, which can change based upon the reset of the rates. Including the amortization of the upfront payments, our effective interest rate as of June 30, 2024, is 6.0%.
The below table summarizes our change in cash, cash equivalents, and restricted cash.
Table MD&A 10: Net Change in Cash and Cash Equivalents and Restricted Cash
(in thousands)
| Operating activities: | For the Nine Months Ended June 30, 2024 | June 30, 2023 |
|---|---|---|
| Net cash provided by operating activities | $351,424 | $169,751 |
| Net cash used in investing activities | (97,165) | (49,739) |
| Net cash used in financing activities | (229,819) | (168,849) |
| Effect of foreign exchange rates on cash and cash equivalents and restricted cash | 1,270 | 3,735 |
| Net change in cash and cash equivalents and restricted cash | $25,710 | $(45,102) |
Net Cash Provided By Operating Activities
Our cash flows from operating activities for the first nine months of fiscal year 2024 increased by $181.7 million, compared to the comparative period in the prior year. This increase was the result of our increased profitability year-over-year, as well as use of our Receivables Purchase Agreement. At June 30, 2024, and September 30, 2023, we had sold $173 million and $72 million of our receivables balance, respectively.
Our Days Sales Outstanding ("DSO") at June 30, 2024, were 59 days, compared with 60 days at September 30, 2023. Excluding the effects of the Receivables Purchase Agreement, DSO would have been 68 days and 65 days, respectively.
Net Cash Used In Investing Activities
We continue to make investments in our capital base, most notably in upgrading technology on our Federal MDE contracts. In addition:
- During fiscal year 2024, we have invested $18 million in acquiring part of one of our long-term vendors;
- During fiscal year 2023, we received payment from the sale of our Swedish business and a small commercial practice in the United Kingdom;
- During fiscal year 2024, we received a further installment payment on the sale of the U.K. business, as well as payment from the sale of our businesses in Italy, Singapore, and our Canadian employment business.
Net Cash Used In Financing Activities
Our principal debt agreement is with JPMorgan Chase Bank N.A. In May 2024, we amended our existing agreement (the "Amended Credit Agreement"). The Amended Credit Agreement extended the maturity dates of our debt and rebalanced our borrowings, but is otherwise broadly consistent with the original arrangement. We have continued to use our operating cash flows to reduce our outstanding debt balance, while maintaining the ability to seek opportunities to build value through M&A activity or our share purchase program. Entering into the Amended Credit Agreement resulted in new financing costs of $9.7 million.
In addition to dividends, we have also purchased Maximus common stock during fiscal year 2024; no such purchases were made in fiscal year 2023.
Our financing cash flows in both fiscal years 2024 and 2023 include transactions in restricted cash funds held by us on behalf of other parties. In fiscal year 2023, these include a payment of $60.7 million to the acquirer of some of our accounts receivable balances, relating to funds received on their behalf.
Credit Facilities
Our principal debt agreement is the Amended Credit Agreement. At June 30, 2024, we owed $1.15 billion under the Amended Credit Agreement, with access to an additional $750 million through a revolving credit facility. Following the amendment, our principal loans mature in May 2029 and May 2031, when the remaining balances must be renegotiated or repaid in full. The revolving facility also matures in May 2029. In addition, our term loans require quarterly mandatory repayments.
The Amended Credit Agreement contains a number of covenants with which we are expected to comply. Failure to meet these requirements would result in a need to renegotiate the agreement, seek a waiver, or a requirement to repay our outstanding debt in full. There are two financial covenants, both defined in the Amended Credit Agreement.
- Our Consolidated Net Total Leverage Ratio means, for any twelve-month period, the ratio of our Funded Debt (as defined by the Amended Credit Agreement), offset by up to $150 million of unrestricted cash (Consolidated Net Total Leverage), against our Consolidated EBITDA (as defined by the Amended Credit Agreement). To comply with our Amended Credit Agreement, this ratio cannot exceed 4.00:1.00 at the end of each quarter, with a step up to 4.50:1.00 under certain circumstances. This ratio also determines both our interest rate and the charge we pay on the unused component of our revolving credit facility, with the charge increasing as the leverage ratio increases.
- Our Consolidated Net Interest Coverage Ratio means, for any twelve-month period, the ratio of our Consolidated EBITDA against our Consolidated Net Interest Expense, as defined by the Amended Credit Agreement. To comply with our Amended Credit Agreement, this ratio cannot be less than 3.00:1.00 at the end of each quarter.
Consolidated EBITDA also drives certain permissions within the Amended Credit Agreement, such as the level of investment we are entitled to make without seeking additional approval from our lenders.
Our Amended Credit Agreement defines Consolidated EBITDA, as well as other components of the calculations above. The definition of Consolidated EBITDA requires us to include adjustments not typically included within EBITDA, including unusual, non-recurring expenses, certain non-cash adjustments, the pro forma effects of acquisitions and disposals, and estimated synergies from acquisitions. As a result, Consolidated EBITDA as defined by the Amended Credit Agreement may not be comparable to EBITDA or related or similarly-titled measures presented by other companies.
We have summarized below the components of our two financial ratio calculations, including the components of Consolidated EBITDA as defined by the Amended Credit Agreement which are included within our financial statements. At June 30, 2024, we were in compliance with all applicable covenants of our Amended Credit Agreement. We do not believe that these covenants represent a significant restriction in our ability to operate our business or to pay our dividends.
Table MD&A 11: Reconciliation of Net Income to Consolidated EBITDA as defined by our Amended Credit Agreement
(in thousands)
| For the Three Months Ended June 30, 2024 | For the Trailing Twelve Months Ended June 30, 2024 | |
|---|---|---|
| Net income | $89,752 | $293,556 |
| Adjustments: | ||
| Interest expense | 20,555 | 82,935 |
| Other expense/(income), net | 809 | 916 |
| Provision for income taxes | 30,623 | 98,459 |
| Amortization of intangibles | 23,542 | 92,524 |
| Stock compensation expense | 9,481 | 34,888 |
| Acquisition-related expenses | 357 | 27 |
| Loss on sale of businesses | — | 1,018 |
| Depreciation and amortization of property, equipment, and capitalized software | 7,530 | 41,779 |
| Pro forma and other adjustments permitted by our Amended Credit Agreement | 17,643 | 70,669 |
| Consolidated EBITDA (as defined by our Amended Credit Agreement) | $200,292 | $716,771 |
(in thousands, except ratio data)
| Table MD&A 12: Consolidated Net Total Leverage Ratio | For the Trailing Twelve Months Ended June 30, 2024 |
|---|---|
| Funded Debt (as defined by our Amended Credit Agreement) | $1,155,003 |
| Cash and cash equivalents up to $150 million | 102,794 |
| Consolidated Net Total Leverage (as defined by our Amended Credit Agreement) | $1,052,209 |
| Consolidated Net Total Leverage Ratio (as defined by our Amended Credit Agreement) | 1.47 |
(in thousands, except ratio data)
| Table MD&A 13: Consolidated Net Interest Coverage Ratio | For the Trailing Twelve Months Ended June 30, 2024 |
|---|---|
| Consolidated EBITDA (as defined by our Amended Credit Agreement) | $716,771 |
| Interest expense | 82,935 |
| Components of other income/expense, net allowed in ratio calculation | 2,454 |
| Consolidated Net Interest Expense (as defined by our Amended Credit Agreement) | $85,389 |
| Consolidated Net Interest Coverage Ratio (as defined by our Amended Credit Agreement) | 8.39 |
Cash in Foreign Locations
We have no requirement to remit funds from our foreign locations to the United States. We will continue to explore opportunities to remit additional funds, taking into consideration the working capital requirements and relevant tax rules in each jurisdiction. When we are unable to remit funds back without incurring a penalty, we will consider these funds indefinitely reinvested until such time as these restrictions are changed. As a result, we do not record U.S. deferred income taxes on any funds held in foreign jurisdictions. We have not attempted to calculate our potential liability from any transfer of these funds, as any such transaction might include tax planning strategies that we have not fully explored. Accordingly, it is not possible to estimate the potential tax obligations if we were to remit all of our funds from foreign locations to the United States.
Free Cash Flow (Non-GAAP)
Table MD&A 14: Free Cash Flow (Non-GAAP)
(in thousands)
| For the Nine Months Ended June 30, 2024 | June 30, 2023 | |
|---|---|---|
| Net cash provided by operating activities | $351,424 | $169,751 |
| Purchases of property and equipment and capitalized software | (82,237) | (58,863) |
| Free cash flow (Non-GAAP) | $269,187 | $110,888 |
Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires us to make estimates, judgments, and assumptions that affect the amounts reported. Actual results could differ from those estimates. The 2023 Form 10-K, as filed with the SEC on November 16, 2023, includes a summary of critical accounting policies we believe are the most important to aid in understanding our financial results. There have been no changes to those critical accounting policies that have had a material impact on our reported amounts of assets, liabilities, revenues, or expenses during the three or nine months ended June 30, 2024.
Non-GAAP and Other Measures
We utilize non-GAAP measures where we believe it will assist users of our financial statements in understanding our business. The presentation of these measures is meant to complement, but not replace, other financial measures in this document. The presentation of non-GAAP numbers is not meant to be considered in isolation, nor as an alternative to revenue growth, cash flows from operating activities, net income, or earnings per share as measures of performance. These non-GAAP measures, as determined and presented by us, may not be comparable to related or similarly titled measures presented by other companies.
For the three months ended June 30, 2024, 12% of our revenue was generated outside the U.S. We believe that users of our financial statements wish to understand the performance of our foreign operations using a methodology that excludes the effect of year-over-year exchange rate fluctuations. To calculate year-over-year currency movement, we determine the current fiscal period's results for all foreign businesses using the exchange rates in the prior fiscal period.
In recent years, we have made a number of acquisitions and divestitures. We believe users of our financial statements wish to evaluate the performance of our operations, excluding changes that have arisen due to businesses acquired or disposed of. We identify acquired revenue and cost of revenue by showing these results for periods for which no comparative results exist within our financial statements. We identify revenue and cost of revenue that has been disposed of in a similar manner. This information is supplemented by our calculations of organic growth. To calculate organic growth, we compare current fiscal period results excluding transactions from acquisitions or disposals, to our prior fiscal period results.
Our recent acquisitions have resulted in significant intangible assets, which are amortized over their estimated useful lives. We believe users of our financial statements wish to understand the performance of the business by using a methodology that excludes the amortization of our intangible assets. For the nine months ended June 30, 2023 and 2024, we also incurred losses on sales of businesses. We believe that providing supplemental measures that exclude the impact of the items detailed below is useful to investors in evaluating our core operations and results in relation to past periods. Accordingly, we have calculated our operating income, net income, and diluted earnings per share, excluding the effect of the amortization of intangible assets and divestiture-related charges. We have included a table showing our reconciliation of these income measures to their corresponding GAAP measures.
Table MD&A 15: Non-GAAP Adjusted Results Excluding Amortization of Intangible Assets and Divestiture-Related Charges
(dollars in thousands, except per share data)
| For the Three Months Ended June 30, 2024 | June 30, 2023 | For the Nine Months Ended June 30, 2024 | June 30, 2023 | |
|---|---|---|---|---|
| Operating income | $141,739 | $58,388 | $376,743 | $195,670 |
| Add back: Amortization of intangible assets | 23,542 | 23,431 | 68,532 | 70,599 |
| Add back: Divestiture-related charges | — | — | 1,018 | 883 |
| Adjusted operating income excluding amortization of intangible assets and divestiture-related charges (Non-GAAP) | $165,281 | $81,819 | $446,293 | $267,152 |
| Adjusted operating income margin excluding amortization of intangible assets and divestiture-related charges (Non-GAAP) | 12.6% | 6.9% | 11.2% | 7.3% |
| Net income | $89,752 | $30,863 | $234,410 | $102,646 |
| Add back: Amortization of intangible assets, net of tax | 17,350 | 17,276 | 50,508 | 52,082 |
| Add back: Divestiture-related charges | — | — | 1,018 | 883 |
| Adjusted net income excluding amortization of intangible assets and divestiture-related charges (Non-GAAP) | $107,102 | $48,139 | $285,936 | $155,611 |
| Diluted earnings per share | $1.46 | $0.50 | $3.81 | $1.67 |
| Add back: Effect of amortization of intangible assets on diluted earnings per share | 0.28 | 0.28 | 0.82 | 0.86 |
| Add back: Effect of divestiture-related charges on diluted earnings per share | — | — | 0.02 | 0.01 |
| Adjusted diluted earnings per share excluding amortization of intangible assets and divestiture-related charges (Non-GAAP) | $1.74 | $0.78 | $4.65 | $2.54 |
In order to sustain our cash flows from operations, we regularly refresh our fixed assets and technology. We believe that users of our financial statements wish to understand the cash flows that directly correspond with our operations and the investments we must make in those operations using a methodology that combines operating cash flows and capital expenditures. We provide free cash flow to complement our statement of cash flows. Free cash flow shows the effects of our operations and replacement capital expenditures and excludes the cash flow effects of acquisitions, purchases of our common stock, dividend payments, and other financing transactions. We have provided a reconciliation of net cash provided by operating activities to free cash flow in "Liquidity and Capital Resources."
To sustain our operations, our principal source of financing comes from receiving payments from our customers. We believe that users of our financial statements wish to evaluate our efficiency in converting revenue into cash receipts. Accordingly, we provide DSO, which we calculate by dividing billed and unbilled receivable balances at the end of each quarter by revenue per day for the quarter. Revenue per day for a quarter is determined by dividing total revenue by 91 days.
Market risk
As filed, 512 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In the normal course of business, we are exposed to financial risks such as changes in interest rates, foreign currency exchange rates, and counterparty risk. We use derivative instruments to manage selected interest rate exposures. The Company's market rate risk disclosures set forth in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" on the 2023 Form 10-K, as filed with the SEC on November 16, 2023, have not changed materially during the nine month period ended June 30, 2024.
Controls and procedures
As filed, 1,542 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that these disclosure controls and procedures were effective and designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 182 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There were no material changes during the nine months ended June 30, 2024, to the risk factors previously disclosed in the 2023 Form 10-K, as filed with the SEC on November 16, 2023.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $1.31bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-10-01 to 2024-06-30 | $3.99bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $982.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2023-10-01 to 2024-06-30 | $3.04bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-04-01 to 2024-06-30 | $332.3m | us-gaap:GrossProfit |
| Gross profit | 9 months2023-10-01 to 2024-06-30 | $950.0m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-04-01 to 2024-06-30 | $167.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-10-01 to 2024-06-30 | $504.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | $141.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-10-01 to 2024-06-30 | $376.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-04-01 to 2024-06-30 | $30.6m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-10-01 to 2024-06-30 | $79.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | $89.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-10-01 to 2024-06-30 | $234.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | $1.46 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-10-01 to 2024-06-30 | $3.81 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | $1.47 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-10-01 to 2024-06-30 | $3.83 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 61,381,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-10-01 to 2024-06-30 | 61,495,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-10-01 to 2024-06-30 | $351.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-10-01 to 2024-06-30 | $82.2m | us-gaap:PaymentsToAcquireProductiveAssets |
| Share repurchases | 9 months2023-10-01 to 2024-06-30 | $47.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-06-30 | $102.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $1.08bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $4.00bn | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $680.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $2.18bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-06-30 | $1.10bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-06-30 | $40.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-06-30 | $1.82bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001032220-24-000075. Last ingested by Listed: Oct 24, 2026, 15:04 ET. Listed shows no prices and gives no investment advice.